Amrutanjan Health Care Limited (AMRUTANJAN.BO)
INR 749.5
(-0.43%)
INR 749.5
(-0.43%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -248.79 Million INR | -522.96% |
| 2022 | -39.93 Million INR | 95.17% |
| 2021 | -826.04 Million INR | 36.14% |
| 2020 | -1.29 Billion INR | -407.98% |
| 2019 | -254.64 Million INR | 65.3% |
| 2018 | -733.82 Million INR | -8.62% |
| 2017 | -675.6 Million INR | -196.04% |
| 2016 | -228.21 Million INR | -16.55% |
| 2015 | -195.81 Million INR | 44.66% |
| 2014 | -353.85 Million INR | -30.05% |
| 2013 | -272.09 Million INR | -18228.96% |
| 2012 | 1.5 Million INR | 101.64% |
| 2011 | -91.27 Million INR | -346.86% |
| 2010 | 36.97 Million INR | 116.27% |
| 2009 | -227.22 Million INR | 66.2% |
| 2008 | -672.25 Million INR | -1281.53% |
| 2007 | 56.89 Million INR | 3531.29% |
| 2006 | -1.65 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | 2.04 Billion INR | 2484.0% |
| 2023 Q4 | -248.79 Million INR | -112.14% |
| 2023 FY | -248.79 Million INR | -522.96% |
| 2023 Q1 | 1.92 Billion INR | 4921.63% |
| 2023 Q2 | -85.93 Million INR | -104.46% |
| 2022 Q1 | 2.05 Billion INR | 348.59% |
| 2022 Q3 | 1.99 Billion INR | 4261.67% |
| 2022 FY | -39.93 Million INR | 95.17% |
| 2022 Q4 | -39.93 Million INR | -102.01% |
| 2022 Q2 | -47.84 Million INR | -102.33% |
| 2021 Q1 | 1.83 Billion INR | 242.21% |
| 2021 FY | -826.04 Million INR | 36.14% |
| 2021 Q2 | -8.56 Million INR | -100.47% |
| 2021 Q4 | -826.04 Million INR | -141.53% |
| 2021 Q3 | 1.98 Billion INR | 23330.71% |
| 2020 FY | -1.29 Billion INR | -407.98% |
| 2020 Q2 | -143.29 Million INR | -120.66% |
| 2020 Q4 | -1.29 Billion INR | -191.26% |
| 2020 Q3 | 1.41 Billion INR | 1089.22% |
| 2020 Q1 | 693.39 Million INR | 372.3% |
| 2019 Q3 | 833.37 Million INR | 752.91% |
| 2019 Q4 | -254.64 Million INR | -130.56% |
| 2019 Q2 | -127.64 Million INR | -114.8% |
| 2019 Q1 | 862.15 Million INR | 217.49% |
| 2019 FY | -254.64 Million INR | 65.3% |
| 2018 Q1 | 778.58 Million INR | 329.19% |
| 2018 FY | -733.82 Million INR | -8.62% |
| 2018 Q4 | -733.82 Million INR | -196.7% |
| 2018 Q3 | 758.9 Million INR | 443.05% |
| 2018 Q2 | -221.22 Million INR | -128.41% |
| 2017 Q4 | -339.7 Million INR | 0.0% |
| 2017 Q1 | 474.49 Million INR | 307.92% |
| 2017 Q2 | -419.54 Million INR | -188.42% |
| 2017 FY | -675.6 Million INR | -196.04% |
| 2016 FY | -228.21 Million INR | -16.55% |
| 2016 Q4 | -228.21 Million INR | 0.0% |
| 2015 FY | -195.81 Million INR | 44.66% |
| 2014 FY | -353.85 Million INR | -30.05% |
| 2013 FY | -272.09 Million INR | -18228.96% |
| 2012 FY | 1.5 Million INR | 101.64% |
| 2012 Q2 | -278.87 Million INR | 0.0% |
| 2012 Q4 | 1.5 Million INR | 0.0% |
| 2011 FY | -91.27 Million INR | -346.86% |
| 2010 FY | 36.97 Million INR | 116.27% |
| 2009 FY | -227.22 Million INR | 66.2% |
| 2008 FY | -672.25 Million INR | -1281.53% |
| 2007 FY | 56.89 Million INR | 3531.29% |
| 2006 FY | -1.65 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | -954.9 Million INR | 73.946% |
| Sigachi Industries Limited | 859.94 Million INR | 128.931% |
| Bal Pharma Limited | 1.26 Billion INR | 119.69% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 94.009% |
| Medico Remedies Limited | 78.67 Million INR | 416.219% |
| Lasa Supergenerics Limited | 205.79 Million INR | 220.891% |
| Venus Remedies Limited | -267.7 Million INR | 7.063% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 73.583% |
| Alpa Laboratories Limited | 35.36 Million INR | 803.538% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 104.041% |
| Shilpa Medicare Limited | 9.06 Billion INR | 102.743% |
| Aarti Drugs Limited | 5.54 Billion INR | 104.484% |
| Lupin Limited | 17.19 Billion INR | 101.447% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 106.736% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 106.36% |
| Windlas Biotech Limited | -273.04 Million INR | 8.881% |
| Suven Life Sciences Limited | -1.63 Billion INR | 84.762% |
| Eris Lifesciences Limited | 13.8 Billion INR | 101.802% |
| Valiant Laboratories Limited | -295.03 Million INR | 15.673% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 108.819% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 102.481% |
| Ipca Laboratories Limited | 11.41 Billion INR | 102.179% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 78.511% |
| Achyut Healthcare Limited | -3.74 Million INR | -6541.538% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 99.657% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 107.542% |
| RPG Life Sciences Limited | -364.7 Million INR | 31.782% |
| Mankind Pharma Limited | -9.9 Billion INR | 97.489% |
| Laurus Labs Limited | 24.38 Billion INR | 101.02% |
| Piramal Pharma Limited | 42.27 Billion INR | 100.588% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 638.383% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 100.782% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 106.436% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 94.194% |
| Unichem Laboratories Limited | 931.91 Million INR | 126.697% |
| Sequent Scientific Limited | 4.17 Billion INR | 105.954% |
| Novartis India Limited | -5.89 Billion INR | 95.777% |
| Wanbury Limited | 1.1 Billion INR | 122.497% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 271.609% |
| Wockhardt Limited | 18.27 Billion INR | 101.362% |
| Themis Medicare Limited | 764.96 Million INR | 132.523% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 82.1% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 100.919% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 91.248% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 101.927% |
| Divi's Laboratories Limited | -39.77 Billion INR | 99.374% |
| NATCO Pharma Limited | -5.81 Billion INR | 95.723% |
| Gufic Biosciences Limited | 3.19 Billion INR | 107.789% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 77.409% |
| Ind-Swift Limited | 9.5 Billion INR | 102.616% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 89.404% |
| FDC Limited | -57.75 Million INR | -330.794% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 112.871% |
| Granules India Limited | 9.28 Billion INR | 102.679% |
| Medicamen Biotech Limited | 160.31 Million INR | 255.189% |
| Alkem Laboratories Limited | -1.6 Billion INR | 84.541% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 95.037% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -1248.759% |
| Brooks Laboratories Limited | 49.48 Million INR | 602.762% |
| Megasoft Limited | 1.28 Billion INR | 119.353% |
| ZIM Laboratories Limited | 983.6 Million INR | 125.294% |
| Strides Pharma Science Limited | 23.25 Billion INR | 101.07% |
| Neuland Laboratories Limited | -214.05 Million INR | -16.226% |
| Morepen Laboratories Limited | -231.17 Million INR | -7.621% |
| Hikal Limited | 7.96 Billion INR | 103.123% |
| Indoco Remedies Limited | 6.47 Billion INR | 103.842% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 109.525% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 307.259% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 125.496% |
| Hester Biosciences Limited | 2.29 Billion INR | 110.861% |